Mergers & Acquisitions ·
Bio-Techne shareholders approved the Merger Agreement with Merck KGaA, Darmstadt, Germany at a special meeting held on…
TECHBIO-TECHNE Corp
Bio-Techne shareholders approved the Merger Agreement with Merck KGaA, Darmstadt, Germany at a special meeting held on September 23, 2026. The proposal received 121,929,544 votes in favor against 1,208,817, representing approval by holders of 78.55% of outstanding shares as of the August 11 record date. The HSR waiting period expired on September 18, 2026, clearing a key regulatory hurdle. Bio-Techne expects the transaction to close in late 2026 or early 2027, pending remaining regulatory approvals and customary conditions. Bio-Techne is a global life sciences company providing reagents, analytical instruments, and diagnostic products.